GLA
IOVA icon

Great Lakes Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Great Lakes Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-104,322
Closed -$772K – 831
2024
Q4 		$772K Sell
104,322
-7,758
-7% -$71.9K 0.01% 604
2024
Q3 		$1.05M Sell
112,080
-13,423
-11% -$127K 0.01% 579
2024
Q2 		$1.01M Sell
125,503
-3,481
-3% -$37.3K 0.01% 574
2024
Q1 		$1.91M Sell
128,984
-7,199
-5% -$83.8K 0.02% 475
2023
Q4 		$1.11M Sell
136,183
-140,351
-51% -$734K 0.01% 518
2023
Q3 		$1.26M Sell
276,534
-7,647
-3% -$49.9K 0.01% 500
2023
Q2 		$2M Sell
284,181
-75,043
-21% -$537K 0.02% 445
2023
Q1 		$2.19M Buy
+359,224
New +$2.48M 0.02% 487

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Great Lakes Advisors's IOVA Position: Q1 2025 in Review

Great Lakes Advisors sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 104,322 shares — an estimated $772K sold.

Great Lakes Advisors first reported a position in IOVA in Q1 2023 and held it in 8 quarters. The position peaked at $2.19M in Q1 2023. 302 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Great Lakes Advisors reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Great Lakes Advisors sold 104,322 Iovance Biotherapeutics shares in Q1 2025, an estimated $772K.
  • Great Lakes Advisors first reported a position in Iovance Biotherapeutics in Q1 2023 and held it in 8 quarters.
  • Great Lakes Advisors's Iovance Biotherapeutics position peaked at $2.19M in Q1 2023.
  • 302 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Great Lakes Advisors's 13F filing for Q1 2025, filed 16 May 2025.